Search Results - "Loi, Sherene"

Intratumoral heterogeneity in cancer progression and response to immunotherapy by Vitale, Ilio, Shema, Efrat, Loi, Sherene, Galluzzi, Lorenzo

“…Most (if not all) tumors emerge and progress under a strong evolutionary pressure imposed by trophic, metabolic, immunological, and therapeutic factors. The…”
Get full text

Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy by Loi, Sherene

“…By analyzing over 2000 samples from a randomized clinical trial, we have recently associated high levels of tumor-infiltrating lymphocytes with an excellent…”
Get full text

Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Where Are We Now and Where Are We Headed? by Dixon-Douglas, Julia, Loi, Sherene

“…Opinion statement Recently, the addition of PD-1 pathway targeting immune checkpoint inhibitors (ICI) to standard neoadjuvant chemotherapy for early-stage…”
Get full text

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer by Turner, Nicholas C, Ro, Jungsil, André, Fabrice, Loi, Sherene, Verma, Sunil, Iwata, Hiroji, Harbeck, Nadia, Loibl, Sibylle, Huang Bartlett, Cynthia, Zhang, Ke, Giorgetti, Carla, Randolph, Sophia, Koehler, Maria, Cristofanilli, Massimo

“…In women with hormone-receptor–positive metastatic breast cancer that had progressed after endocrine therapy, palbociclib plus fulvestrant was associated with…”
Get full text

Seeing the forest and the tree: TILs and PD-L1 as immune biomarkers by Savas, Peter, Salgado, Roberto, Loi, Sherene

“…Here we will provide an immune-focussed overview of biomarkers in early and advanced stage breast cancer. It should be noted from the outset that all the…”
Get full text

Clinical relevance of host immunity in breast cancer: from TILs to the clinic by Savas, Peter, Salgado, Roberto, Denkert, Carsten, Sotiriou, Christos, Darcy, Phillip K., Smyth, Mark J., Loi, Sherene

“…Key Points The detection of tumour-infiltrating lymphocytes (TILs) on routine histology constitutes a robust prognostic and predictive biomarker in patients…”
Get full text

Triple-negative breast cancer: recent treatment advances [version 1; peer review: 2 approved] by Bergin, Alice R T, Loi, Sherene

“…Triple-negative breast cancer (TNBC) is a breast cancer subtype renowned for its capacity to affect younger women, metastasise early despite optimal adjuvant…”
Get full text

Precision medicine for metastatic breast cancer—limitations and solutions by Arnedos, Monica, Vicier, Cecile, Loi, Sherene, Lefebvre, Celine, Michiels, Stefan, Bonnefoi, Herve, Andre, Fabrice

“…Key Points Recent research data defining the genomic landscape of breast cancer have reinforced the notion that this disease is driven by genomic alterations…”
Get full text

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer by Cortes, Javier, Rugo, Hope S., Cescon, David W., Im, Seock-Ah, Yusof, Mastura M., Gallardo, Carlos, Lipatov, Oleg, Barrios, Carlos H., Perez-Garcia, Jose, Iwata, Hiroji, Masuda, Norikazu, Torregroza Otero, Marco, Gokmen, Erhan, Loi, Sherene, Guo, Zifang, Zhou, Xuan, Karantza, Vassiliki, Pan, Wilbur, Schmid, Peter

“…Among patients with triple-negative breast cancer and high expression of PD-L1, pembrolizumab plus chemotherapy resulted in longer overall survival than…”
Get full text

Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers by Loi, Sherene, Drubay, Damien, Adams, Sylvia, Pruneri, Giancarlo, Francis, Prudence A, Lacroix-Triki, Magali, Joensuu, Heikki, Dieci, Maria Vittoria, Badve, Sunil, Demaria, Sandra, Gray, Robert, Munzone, Elisabetta, Lemonnier, Jerome, Sotiriou, Christos, Piccart, Martine J, Kellokumpu-Lehtinen, Pirkko-Liisa, Vingiani, Andrea, Gray, Kathryn, Andre, Fabrice, Denkert, Carsten, Salgado, Roberto, Michiels, Stefan

“…The aim of the current study was to conduct a pooled analysis of studies that have investigated the prognostic value of tumor-infiltrating lymphocytes (TILs)…”
Get full text

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer by Schmid, Peter, Adams, Sylvia, Rugo, Hope S, Schneeweiss, Andreas, Barrios, Carlos H, Iwata, Hiroji, Diéras, Véronique, Hegg, Roberto, Im, Seock-Ah, Shaw Wright, Gail, Henschel, Volkmar, Molinero, Luciana, Chui, Stephen Y, Funke, Roel, Husain, Amreen, Winer, Eric P, Loi, Sherene, Emens, Leisha A

“…Addition of the anti–PD-L1 antibody atezolizumab to nab-paclitaxel as first-line therapy for patients with advanced or metastatic triple-negative breast cancer…”
Get full text

Tissue-resident memory T cells in breast cancer control and immunotherapy responses by Byrne, Ann, Savas, Peter, Sant, Sneha, Li, Ran, Virassamy, Balaji, Luen, Stephen J., Beavis, Paul A., Mackay, Laura K., Neeson, Paul J., Loi, Sherene

“…The presence of tumour-infiltrating lymphocytes (TILs) is associated with favourable outcomes in patients with breast cancer as well as in those with other…”
Get full text

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer by Turner, Nicholas C, Slamon, Dennis J, Ro, Jungsil, Bondarenko, Igor, Im, Seock-Ah, Masuda, Norikazu, Colleoni, Marco, DeMichele, Angela, Loi, Sherene, Verma, Sunil, Iwata, Hiroji, Harbeck, Nadia, Loibl, Sibylle, André, Fabrice, Puyana Theall, Kathy, Huang, Xin, Giorgetti, Carla, Huang Bartlett, Cynthia, Cristofanilli, Massimo

“…The addition of palbociclib to fulvestrant prolonged overall survival among women with hormone receptor–positive, HER2-negative advanced breast cancer who had…”
Get full text

The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial by O'Leary, Ben, Cutts, Rosalind J, Liu, Yuan, Hrebien, Sarah, Huang, Xin, Fenwick, Kerry, André, Fabrice, Loibl, Sibylle, Loi, Sherene, Garcia-Murillas, Isaac, Cristofanilli, Massimo, Huang Bartlett, Cynthia, Turner, Nicholas C

“…CDK4/6 inhibition with endocrine therapy is now a standard of care for advanced estrogen receptor-positive breast cancer. Mechanisms of CDK4/6 inhibitor…”
Get more information

Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study by Emens, Leisha A, Molinero, Luciana, Loi, Sherene, Rugo, Hope S, Schneeweiss, Andreas, Diéras, Véronique, Iwata, Hiroji, Barrios, Carlos H, Nechaeva, Marina, Nguyen-Duc, Anh, Chui, Stephen Y, Husain, Amreen, Winer, Eric P, Adams, Sylvia, Schmid, Peter

“…Abstract Background Understanding the impact of the tumor immune microenvironment and BRCA1/2-related DNA repair deficiencies on the clinical activity of…”
Get full text

Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade by House, Imran G, Savas, Peter, Lai, Junyun, Chen, Amanda X Y, Oliver, Amanda J, Teo, Zhi L, Todd, Kirsten L, Henderson, Melissa A, Giuffrida, Lauren, Petley, Emma V, Sek, Kevin, Mardiana, Sherly, Gide, Tuba N, Quek, Camelia, Scolyer, Richard A, Long, Georgina V, Wilmott, James S, Loi, Sherene, Darcy, Phillip K, Beavis, Paul A

“…Response rates to immune checkpoint blockade (ICB; anti-PD-1/anti-CTLA-4) correlate with the extent of tumor immune infiltrate, but the mechanisms underlying…”
Get full text

Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer by Turner, Nicholas C, Liu, Yuan, Zhu, Zhou, Loi, Sherene, Colleoni, Marco, Loibl, Sibylle, DeMichele, Angela, Harbeck, Nadia, André, Fabrice, Bayar, Mohamed Amine, Michiels, Stefan, Zhang, Zhe, Giorgetti, Carla, Arnedos, Monica, Huang Bartlett, Cynthia, Cristofanilli, Massimo

“…A large-panel gene expression analysis was conducted to identify biomarkers associated with the effectiveness of adding palbociclib to fulvestrant. The…”
Get full text

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer by Fribbens, Charlotte, O'Leary, Ben, Kilburn, Lucy, Hrebien, Sarah, Garcia-Murillas, Isaac, Beaney, Matthew, Cristofanilli, Massimo, Andre, Fabrice, Loi, Sherene, Loibl, Sibylle, Jiang, John, Bartlett, Cynthia Huang, Koehler, Maria, Dowsett, Mitch, Bliss, Judith M, Johnston, Stephen R D, Turner, Nicholas C

“…ESR1 mutations are selected by prior aromatase inhibitor (AI) therapy in advanced breast cancer. We assessed the impact of ESR1 mutations on sensitivity to…”
Get full text

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial by Cristofanilli, Massimo, Prof, Turner, Nicholas C, MD, Bondarenko, Igor, Prof, Ro, Jungsil, MD, Im, Seock-Ah, MD, Masuda, Norikazu, MD, Colleoni, Marco, MD, DeMichele, Angela, MD, Loi, Sherene, MD, Verma, Sunil, MD, Iwata, Hiroji, MD, Harbeck, Nadia, Prof, Zhang, Ke, PhD, Theall, Kathy Puyana, MD, Jiang, Yuqiu, PhD, Bartlett, Cynthia Huang, MD, Koehler, Maria, MD, Slamon, Dennis, Prof

“…Summary Background In the PALOMA-3 study, the combination of the CDK4 and CDK6 inhibitor palbociclib and fulvestrant was associated with significant…”
Get full text

Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer by Rugo, Hope S, Delord, Jean-Pierre, Im, Seock-Ah, Ott, Patrick A, Piha-Paul, Sarina A, Bedard, Philippe L, Sachdev, Jasgit, Le Tourneau, Christophe, van Brummelen, Emilie M J, Varga, Andrea, Salgado, Roberto, Loi, Sherene, Saraf, Sanatan, Pietrangelo, Dina, Karantza, Vassiliki, Tan, Antoinette R

“…We investigated the safety and antitumor activity of the anti-programmed death 1 monoclonal antibody pembrolizumab in patients with estrogen receptor-positive…”
Get full text